PPHM : Analysis & Opinions

  1. Analyst Bullish on Peregrine Following Q2 Update

    July 22, 2015
    Following earnings and with $68 million cash on hand, Peregrine biopharmaceutical is now planning several new studies. Roth ...
  2. 3 Reasons Peregrine's Stock Could Fall

    June 30, 2015
    Small-cap biopharmaceutical company Peregrine Pharmaceuticals (NASDAQ: PPHM) could be sitting in the sweet spot when it ...
  3. Spotlight on Peregrine's Bavituximab Expansion

    June 3, 2015
    Shareholders of clinical-stage biopharmaceutical company Peregrine Pharmaceuticals (NASDAQ: PPHM) haven't fared well over ...
  4. 3 Reasons Peregrine's Stock Could Rise

    May 13, 2015
    Peregrine Pharmaceuticals (NASDAQ: PPHM) is a small-cap biotech stock valued at only $250 million, but if its pipeline follows ...
  5. 3 Keys to Success for Peregrine Pharmaceuticals

    March 20, 2015
    Buying small-cap pharmaceutical companies might be for investors the equivalent of placing a bet at a Las Vegas roulette ...
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!